LQDA

AI Memo

Liquidia

As of 2026-09-01/Confidence high/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-01 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

6‑12m

Key catalyst

Q2 2026 commercial and profitability inflection • 2026-08-12

Base target: $76 / p=50% prob

Biggest risk

The bear case is that high expectations already discount much of the launch trajectory, while clinical development remains date-uncertain and recent insider sales may create pressure. Analyst revision and target-change data are unavailable, so the post-print thesis lacks independent estimate confirmation.

Invalidation

Break below $52 or thesis failure.

What would change my mind?

The bull case rests on strong YUTREPIA uptake, rapid sequential sales growth, expanding prescriber adoption, improving profitability, and potential upside from L606 and additional indications. Company-reported Q2 results provide strong primary-source support. [#SEC-8K-2026-08-12]

Research note

Recommendation

—

Confidence

high

As of

2026-09-01

Base target

$76

p=50%

Bull target

$92

p=25%

Bear target

$52

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Recent insider selling adds near-term supply risk
Continued YUTREPIA adoption and share gains
L606 Re-Spire and broader indication development

BearKey bullets

Analyst estimate, rating, and target revisions are unavailable.
Clinical development and Re-Spire execution have no disclosed readout timeline.
Recent officer and director open-market sales may increase near-term supply pressure.

WatchKey bullets

Q2 2026 commercial and profitability inflection

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $76 (p=50%)

Target spread vs base: +21% / -32%

Scenario probabilities

Bull Target: $92 (p=25%)Base Target: $76 (p=50%)Bear Target: $52 (p=25%)

Commentary

News tone is positive and centered on the Q2 sales, adoption, profitability, and clinical-development update. Social, options, short-interest, and employee-sentiment measures are unavailable; zero values are placeholders, not neutral readings. The earnings-related price context is constructive, but missing analyst revisions and recent insider sales argue for monitoring rather than an aggressive signal.

As of 2026-09-01 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Recent insider selling adds near-term supply risk
Continued YUTREPIA adoption and share gains
L606 Re-Spire and broader indication development

Scenarios

Bull Target (Scenario probability)

$92 / p=25% prob

Base Target (Scenario probability)

$76 / p=50% prob

Bear Target (Scenario probability)

$52 / p=25% prob

Analysis 2026-09-01 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.72

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-12
Q2 2026 commercial and profitability inflection
YUTREPIA net product sales reached approximately $170.4 million, up 31% sequentially; Liquidia reported $74.7 million net income, $96.3 million adjusted EBITDA, and more than 5,000 treated patients. [#SEC-8K-2026-08-12]
Prob 90.00% • Move 12.00% • Priced-in 80.00%

Short-term Catalysts

Next few weeks

Recent insider selling adds near-term supply risk
2026-11-30
Recent Form 4 filings show open-market sales by company officers and a director after the earnings-related share-price appreciation. These filings support a supply and sentiment risk, but do not establish a change in operating performance. [#SEC-FORM4-2026-08-25]
Prob 65% • Move -8% • Priced-in 45%

Long-term Catalysts

Months to a year

Continued YUTREPIA adoption and share gains
2027-09-01
Management reported approximately 5,900 prescriptions, more than 5,000 treated patients, over 1,100 prescribers, and sustained prescription-to-start conversion above 85%. Continued execution could support further revenue and cash-flow growth, although much of the success is reflected in the valuation. [#SEC-8K-2026-08-12]
Prob 75% • Move 18% • Priced-in 65%
L606 Re-Spire and broader indication development
2027-09-01
Liquidia reported progress across 10 clinical studies and site activation and enrollment in the pivotal Phase 3 Re-Spire study for L606, while expanding YUTREPIA evidence in PAH and PH-ILD. No readout date is disclosed. [#SEC-8K-2026-08-12]
Prob 55% • Move 28% • Priced-in 35%

Risks

Analyst estimate, rating, and target revisions are unavailable.
Clinical development and Re-Spire execution have no disclosed readout timeline.
Recent officer and director open-market sales may increase near-term supply pressure. [#SEC-FORM4-2026-08-25]
Valuation is exposed to disappointment after strong launch performance.
YUTREPIA growth, prescription conversion, or market-share gains could decelerate.

Peers

Symbol	Summary
BLTE	Same-sector market-cap neighbor, but direct operating comparability with Liquidia's commercial inhaled treprostinil franchise is not established; low-confidence reference.
CGON	Same-sector biotechnology neighbor with a different development profile; useful only as a broad biotech sentiment reference, not a direct peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-01

Loading AI feed…

Symbol

Summary

BLTE

Same-sector market-cap neighbor, but direct operating comparability with Liquidia's commercial inhaled treprostinil franchise is not established; low-confidence reference.

CGON

Same-sector biotechnology neighbor with a different development profile; useful only as a broad biotech sentiment reference, not a direct peer.